There is a push towards devices/testing at POC (point of care; think on spot pathology tests, portable x-rays/screening), this is an expanding segment in healthcare.
MX1 and EMV are both approaching a portable screening device but with different tech
MX1
- Miniaturised x-ray process
- FDA approval for some products
- Manufacturing
- Revenue/cash
EMV
Both were awarded grants by the stroke alliance Aust for an in ambulance solution, critical in saving lives. If the ambos can determine if the cause is a blood clot or brain bleed, treatment can be given on the spot. Time delay is critical in having good outcomes for stroke patients.
It’s unclear who is ahead in the stroke detection device, both are in testing phases.
EMV is solely focused on the stroke detection device, MX1 has products from portable infield x-rays to luggage scanners for airports.
International Competition – Nanox
Israeli company listed in the US recently to much fanfare. Also tackling the smaller x-ray device as per MX1. FDA approval for its 1st device Apr this year.
Nanox is also tackling cloud storage and AI detection of scans, unsure if this is innovative tech as it already exist in various forms. Major selling point seems to be targeting reduced costs and efficiency.
Held MX1, Watching EMV
